Pharmacogenomic Information onRituximab

Pharmacogenomic Information

DrugTherapeutic Area*
Labeling Sections
RituximabOncologyMS4A1CD20 antigen positiveIndications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies


* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 02/22/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.